Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2019
09 août 2019 07h00 HE
|
Axovant Sciences Ltd.
SUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019Data from patients dosed...
Axovant Appoints David Nassif as Chief Financial Officer and Expands Board of Directors
01 juil. 2019 07h00 HE
|
Axovant Sciences Ltd.
-David Nassif joins executive management team as CFO, effective July 1, 2019- -Senthil Sundaram to join Axovant’s Board of Directors- BASEL, Switzerland, July 01, 2019 (GLOBE NEWSWIRE) -- Axovant...
Axovant Announces Poster Presentations at the 5th Congress of the European Academy of Neurology
24 juin 2019 07h01 HE
|
Axovant Sciences Ltd.
-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and AXO-AAV-GM2 program highlighted in poster presentations- BASEL, Switzerland, June 24, 2019 (GLOBE NEWSWIRE) -- Axovant Gene...
Axovant and Yposkesi Sign Strategic Gene Therapy Development and Manufacturing Partnership
20 juin 2019 07h00 HE
|
Axovant Sciences Ltd.
BASEL, Switzerland and CORBEIL-ESSONNES, France, June 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today...
Axovant Announces Financial Results and Corporate Updates for Fourth Quarter and Fiscal Year Ended March 31, 2019
11 juin 2019 16h05 HE
|
Axovant Sciences Ltd.
Established diversified pipeline of three clinical-stage gene therapy programs for serious neurological disorders including Parkinson’s disease, GM1 gangliosidosis, and Tay-Sachs SUNRISE-PD Phase 2...
Axovant Announces 6-Month Follow-Up Data From First Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD and Pipeline Update
06 juin 2019 07h40 HE
|
Axovant Sciences Ltd.
AXO-Lenti-PD was observed to be generally well tolerated at six months, and continued to demonstrate benefits in both patients across multiple measures after a single administrationTotality of data...
Axovant to Present at Upcoming Conferences in June
31 mai 2019 07h00 HE
|
Axovant Sciences Ltd.
BASEL, Switzerland, May 31, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu,...
Axovant to Present at 2019 RBC Capital Markets Global Healthcare Conference
20 mai 2019 07h00 HE
|
Axovant Sciences Ltd.
BASEL, Switzerland, May 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu,...
Axovant Announces Dosing of First Patient in Clinical Program for AXO-AAV-GM1, a Novel Gene Therapy for GM1 Gangliosidosis
16 mai 2019 16h05 HE
|
Axovant Sciences Ltd.
- Milestone marks the first patient with GM1 gangliosidosis treated with gene therapy- -Initial data expected in second half of 2019- -AXO-AAV-GM1 is Axovant’s third investigational gene therapy...
Axovant Announces Reverse Share Split Effectiveness
07 mai 2019 16h15 HE
|
Axovant Sciences Ltd.
Shares to begin trading on split-adjusted basis on May 8, 2019 BASEL, Switzerland, May 07, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing...